VIROPTIC
Details
- Status
- Prescription
- First Approved
- 1980-04-10
- Routes
- OPHTHALMIC
- Dosage Forms
- SOLUTION/DROPS
VIROPTIC Approval History
What VIROPTIC Treats
2 indicationsVIROPTIC is approved for 2 conditions since its original approval in 1980. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Keratoconjunctivitis
- Epithelial Keratitis
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
VIROPTIC FDA Label Details
ProIndications & Usage
: Trifluridine Ophthalmic Solution is indicated for the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2.
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.